KR102638151B1 - 키나아제 억제제 및 이의 용도 - Google Patents

키나아제 억제제 및 이의 용도 Download PDF

Info

Publication number
KR102638151B1
KR102638151B1 KR1020197036911A KR20197036911A KR102638151B1 KR 102638151 B1 KR102638151 B1 KR 102638151B1 KR 1020197036911 A KR1020197036911 A KR 1020197036911A KR 20197036911 A KR20197036911 A KR 20197036911A KR 102638151 B1 KR102638151 B1 KR 102638151B1
Authority
KR
South Korea
Prior art keywords
disease
formula
alkyl
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197036911A
Other languages
English (en)
Korean (ko)
Other versions
KR20200006125A (ko
Inventor
자비에르 드 비센테 피달고
앤서니 에이. 에스트라다
지안웬 에이. 펭
브라이언 폭스
신치아 마리아 프란치니
크리스토퍼 알.에이치. 헤일
청 후
콜린 필립 레슬리
막심 오시포브
엘레나 세라
자카리 케이. 스위니
아룬 토툼카라
Original Assignee
데날리 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데날리 테라퓨틱스 인크. filed Critical 데날리 테라퓨틱스 인크.
Publication of KR20200006125A publication Critical patent/KR20200006125A/ko
Application granted granted Critical
Publication of KR102638151B1 publication Critical patent/KR102638151B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/04—Seven-membered rings having the hetero atoms in positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020197036911A 2017-05-17 2018-05-17 키나아제 억제제 및 이의 용도 Active KR102638151B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762507698P 2017-05-17 2017-05-17
US62/507,698 2017-05-17
US201862664895P 2018-04-30 2018-04-30
US62/664,895 2018-04-30
PCT/US2018/033266 WO2018213632A1 (en) 2017-05-17 2018-05-17 Kinase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
KR20200006125A KR20200006125A (ko) 2020-01-17
KR102638151B1 true KR102638151B1 (ko) 2024-02-16

Family

ID=64274744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197036911A Active KR102638151B1 (ko) 2017-05-17 2018-05-17 키나아제 억제제 및 이의 용도

Country Status (21)

Country Link
US (3) US11203600B2 (enExample)
EP (1) EP3624797A4 (enExample)
JP (2) JP7064512B2 (enExample)
KR (1) KR102638151B1 (enExample)
CN (3) CN119264073A (enExample)
AU (1) AU2018269743B2 (enExample)
BR (1) BR112019023918A2 (enExample)
CA (1) CA3063934A1 (enExample)
CL (1) CL2019003263A1 (enExample)
CO (1) CO2019012957A2 (enExample)
CR (1) CR20190566A (enExample)
DO (1) DOP2019000290A (enExample)
EC (1) ECSP19089214A (enExample)
IL (1) IL270648B2 (enExample)
MX (2) MX2019013645A (enExample)
MY (1) MY200328A (enExample)
PE (2) PE20241932A1 (enExample)
PH (1) PH12019550235A1 (enExample)
SG (1) SG10201913927VA (enExample)
TW (1) TWI794232B (enExample)
WO (1) WO2018213632A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7273954B2 (ja) * 2018-10-19 2023-05-15 ディスアーム セラピューティクス， インコーポレイテッド Ｎａｄ＋またはｎａｄ＋前駆体と組み合わせたｓａｒｍ１の阻害
IL291665B2 (en) * 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
TW202535863A (zh) * 2020-02-13 2025-09-16 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
WO2021187605A1 (ja) * 2020-03-19 2021-09-23 田辺三菱製薬株式会社 含窒素複素環αシアノカルボニル化合物
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途
KR200493347Y1 (ko) 2020-07-06 2021-03-17 박혜진 휴대가 용이한 마스크
US20240327412A1 (en) * 2021-02-19 2024-10-03 Kalvista Pharmaceuticals Limited Factor xiia inhibitors
US20240208986A1 (en) * 2021-04-27 2024-06-27 Merck Sharp & Dohme Llc Phenyl azepines as ripk1 inhibitors and methods of use thereof
EP4329766A4 (en) * 2021-04-27 2025-06-11 Merck Sharp & Dohme LLC RIPK1 INHIBITORS AND METHODS OF USE
WO2023083847A1 (en) 2021-11-11 2023-05-19 Sanofi Isoxazolidines as ripk1 inhibitors and use thereof
TW202417453A (zh) * 2022-07-25 2024-05-01 美商戴納立製藥公司 ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶並［３，４－ｆ］［１，４］氧氮呯－９－甲腈的固體形式
WO2024044151A1 (en) * 2022-08-23 2024-02-29 Genzyme Corporation Methods for treating receptor-interacting protein kinase 1-mediated diseases
TW202444357A (zh) * 2023-01-23 2024-11-16 美商健臻公司 ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶并［３，４－ｆ］［１，４］氧氮呯－９－甲腈之藥品調配物
TW202515552A (zh) * 2023-06-27 2025-04-16 美商健臻公司 製備4-(3,3-二氟-2,2-二甲基-丙醯基)-3,5-二氫-2h-吡啶并[3,4-f][1,4]氧雜氮呯-9-腈之方法
CN120365288A (zh) * 2024-01-23 2025-07-25 南京天印健华医药科技有限公司 作为ripk1抑制剂的杂环化合物
CN120365287A (zh) * 2024-01-23 2025-07-25 南京天印健华医药科技有限公司 作为ripk1抑制剂的杂环化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140100216A1 (en) * 2011-05-20 2014-04-10 Nikolay Filippovich Savchuk Stimulators of incretin hormones secretion, method for preparation and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3861187B2 (ja) * 1996-08-02 2006-12-20 住友精化株式会社 チアゼピン誘導体の製造方法
MXPA03002649A (es) 2000-09-27 2003-09-25 Ajinomoto Kk Derivado de benzodiazepina.
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
TWI648274B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 （二）
CN104059068B (zh) 2013-03-20 2017-02-08 中国科学院上海药物研究所 β‑氨基羰基类化合物、其制备方法、药物组合物及其用途
CN107801396B (zh) * 2015-02-02 2021-10-22 福马治疗股份有限公司 作为hdac抑制剂的3-芳基-4-酰氨基-二环[4,5,0]异羟肟酸
UY36680A (es) * 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
PH12017502255B1 (en) * 2015-06-15 2022-07-22 Astex Therapeutics Ltd Nrf2 regulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140100216A1 (en) * 2011-05-20 2014-04-10 Nikolay Filippovich Savchuk Stimulators of incretin hormones secretion, method for preparation and use thereof

Also Published As

Publication number Publication date
US11203600B2 (en) 2021-12-21
JP7241825B2 (ja) 2023-03-17
US20200087319A1 (en) 2020-03-19
CN119264073A (zh) 2025-01-07
CA3063934A1 (en) 2018-11-22
JP7064512B2 (ja) 2022-05-10
PH12019550235A1 (en) 2020-07-20
CN119285572A (zh) 2025-01-10
US12129263B2 (en) 2024-10-29
MX2022010755A (es) 2022-09-23
IL270648B2 (en) 2024-03-01
IL270648B1 (en) 2023-11-01
US20220041620A1 (en) 2022-02-10
JP2020520924A (ja) 2020-07-16
SG10201913927VA (en) 2020-03-30
BR112019023918A2 (pt) 2020-06-02
ECSP19089214A (es) 2020-05-29
PE20200729A1 (es) 2020-07-23
EP3624797A1 (en) 2020-03-25
JP2021193116A (ja) 2021-12-23
TWI794232B (zh) 2023-03-01
PE20241932A1 (es) 2024-09-24
CR20190566A (es) 2020-06-14
WO2018213632A1 (en) 2018-11-22
MY200328A (en) 2023-12-20
MX2019013645A (es) 2020-09-17
US20250011338A1 (en) 2025-01-09
CN110913858A (zh) 2020-03-24
KR20200006125A (ko) 2020-01-17
CL2019003263A1 (es) 2020-04-17
DOP2019000290A (es) 2020-03-15
TW201900618A (zh) 2019-01-01
AU2018269743B2 (en) 2024-01-11
AU2018269743A1 (en) 2020-01-16
CN110913858B (zh) 2024-09-24
EP3624797A4 (en) 2021-07-21
IL270648A (enExample) 2020-01-30
CO2019012957A2 (es) 2020-05-29

Similar Documents

Publication Publication Date Title
KR102638151B1 (ko) 키나아제 억제제 및 이의 용도
US10258626B2 (en) Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
KR102172742B1 (ko) Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
DE602004006169T2 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
AU2016280137B2 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
AU2013290054A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
CA2953798A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
KR20210049895A (ko) 고 활성 sting 단백질 작용제 화합물
CA3163389A1 (en) Biphenyl derivative inhibitor, preparation method therefor and use thereof
ES2869129T3 (es) Agonistas de piperidinona del receptor 2 de péptidos formilados
CA3080623C (en) Compound having erk kinase inhibitory activity and use thereof
HK1230164B (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191213

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210514

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230302

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230713

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230302

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230713

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230502

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210514

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20231122

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20231113

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230713

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230502

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210514

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240214

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240214

End annual number: 3

Start annual number: 1

PG1601 Publication of registration